Rossari Biotech Ltd (ROSSARI) AI Stock Analysis

• Market Cap: ₹34.89B
• Dividend Yield: 0.08%
• Average Volume (3M): 3.87K
• Price to Earnings (P/E): 25.8
• Beta (1Y): 1.00
• Revenue Growth: 11.77%
• EPS Growth: -1.14%
• Country: IN
• Employees: 450
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 6.10
• Shares Outstanding: 55,366,966
• 10 Day Avg. Volume: 4,423
• 30 Day Avg. Volume: 3,866
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹718.50
• Price Target Upside: 14.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 64 Neutral
• Price Target: ₹677.00 ▲(7.44% Upside)

Rossari Biotech Ltd shows strong financial performance with robust revenue growth and profitability. However, technical indicators suggest a bearish trend, and the valuation appears high with a low dividend yield. Improving free cash flow and reversing the negative technical trend are crucial for enhancing the stock's attractiveness.

Rossari Biotech Ltd Business Overview & Revenue Model

Company Description

Rossari Biotech Ltd (ROSSARI) is a prominent Indian specialty chemicals company, primarily focusing on providing customized solutions for various sectors, including home, personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition. The company is recognized for its innovative approach in developing sustainable and environmentally friendly products, catering to a diverse range of industries both domestically and internationally.

How the Company Makes Money

Rossari Biotech Ltd generates revenue through the manufacturing and sale of specialty chemicals across various sectors. Its key revenue streams include home and personal care chemicals, textile specialty chemicals, and animal health and nutrition products. The company collaborates with a wide array of industries to provide tailored chemical solutions that enhance product performance and efficiency. Significant partnerships with major industry players and a strong distribution network contribute to its earnings, allowing it to maintain a competitive edge in the specialty chemicals market.

Rossari Biotech Ltd Financial Statement Overview

Summary

Rossari Biotech Ltd exhibits strong revenue growth and profitability, with efficient use of equity and low leverage. However, the company faces challenges in generating positive free cash flow due to high capital expenditures.

Income Statement

Rossari Biotech Ltd has demonstrated a strong revenue growth rate of 13.65% from 2024 to 2025, with a notable improvement in both gross profit margin (31.10%) and EBIT margin (24.74%) in 2025. Net profit margin increased slightly to 6.55%, reflecting efficient cost management and operational performance. However, EBITDA margin decreased slightly to 12.74%, indicating some pressure on operational cash generation.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.18, indicating low leverage and a strong equity position. The return on equity improved to 11.51%, demonstrating effective use of equity to generate profits. The equity ratio stands at 62.51%, indicating a solid financial structure with a significant portion of assets funded by equity.

Cash Flow

Operating cash flow to net income ratio is 1.01, showing that operating cash flow adequately covers net income. However, free cash flow remains negative, reflecting high capital expenditures relative to operating cash flow. The free cash flow to net income ratio is negative, posing potential liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	20.80B	20.80B	18.31B	16.56B	14.83B	7.07B
Gross Profit	5.55B	6.47B	5.26B	4.85B	3.64B	2.29B
EBITDA	2.66B	2.65B	2.57B	2.12B	1.94B	1.31B
Net Income	1.36B	1.36B	1.31B	1.07B	976.74M	802.20M
Balance Sheet
Total Assets	18.96B	18.96B	15.72B	13.68B	12.57B	5.61B
Cash, Cash Equivalents and Short-Term Investments	1.14B	1.14B	667.85M	1.52B	644.26M	883.57M
Total Debt	2.18B	2.18B	1.19B	739.28M	84.27M	0.00
Total Liabilities	7.11B	7.11B	5.24B	4.52B	4.52B	1.53B
Stockholders Equity	11.85B	11.85B	10.48B	9.15B	8.05B	4.09B
Cash Flow
Free Cash Flow	0.00	-210.69M	-880.28M	1.20B	-88.67M	-103.17M
Operating Cash Flow	0.00	1.37B	432.55M	1.52B	293.58M	477.67M
Investing Cash Flow	0.00	-1.84B	-1.03B	-1.81B	-2.99B	-371.79M
Financing Cash Flow	0.00	649.01M	161.85M	608.55M	2.92B	-245.92M

Rossari Biotech Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 630.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Negative. The current price of 630.1 is below the 20-day moving average (MA) of 637.22, below the 50-day MA of 657.43, and below the 200-day MA of 688.63, indicating a bearish trend. The MACD of -0.76 indicates Negative momentum. The RSI at 43.91 is Neutral, neither overbought nor oversold. The STOCH value of 16.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ROSSARI.

Rossari Biotech Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FCL	68 Neutral	28.67B	27.52	14.80%	0.32%	-8.66%	-17.79%
BHARATRAS	65 Neutral	41.26B	30.02	12.47%	0.01%	16.60%	4.50%
KIRIINDUS	65 Neutral	33.95B	16.64	8.15%	―	-12.76%	-17.59%
ROSSARI	64 Neutral	₹34.89B	25.81	―	0.08%	11.77%	-1.14%
ORISSAMINE	46 Neutral	28.88B	-70.55	77.99%	―	-24.40%	-361.49%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

Rossari Biotech Ltd Corporate Events

Rossari Biotech Ltd Holds Successful 16th AGM, Secures Shareholder Approval for Key Resolutions

Rossari Biotech Ltd successfully conducted its 16th Annual General Meeting (AGM) on June 30, 2025, via video conferencing, adhering to regulatory guidelines. All resolutions proposed during the meeting were approved by the requisite majority, reflecting strong shareholder support and potentially reinforcing the company’s strategic direction.